Abstract
G protein-coupled receptors (GPCRs) are recognized as critical therapeutic targets in bone disorders, owing to their multifaceted regulatory roles across diverse bone cell lineages. This review systematically catalogs GPCR expression and functional heterogeneity in key bone cells: 12 GPCRs in mesenchymal stem cells (MSCs) orchestrate lineage specification; 21 GPCRs in osteoblasts/osteocytes mediate matrix mineralization and mechanotransduction; 23 GPCRs in macrophages/osteoclasts regulate inflammatory bone resorption; 31 GPCRs in chondrocytes govern endochondral ossification and osteoarthritis pathogenesis; and 8 GPCRs in other cell types modulate bone-related physiological processes. By integrating canonical signaling axes-cAMP/PKA-dependent transcriptional networks, PLC-β/IP3-driven calcium signaling, and NF-κB-modulated immuno-skeletal interactions-we elucidate how GPCRs dynamically coordinate cellular plasticity to maintain skeletal homeostasis. This work establishes a multidimensional research framework integrating historical context, molecular mechanisms, and cutting-edge methodologies to advance GPCR-targeted therapies for bone-related diseases. Moreover, this review provides insights for clinical translation, including biased agonism and allosteric modulation precision strategies to restore skeletal equilibrium in osteoporosis, arthritis, and regenerative medicine.
Introduction
Bone is not a static scaffold; it is a highly dynamic tissue constantly being built, destroyed, and repaired through a process called remodeling. This process relies on a delicate balance between different cell types: Mesenchymal Stem Cells (MSCs), bone-building osteoblasts, bone-resorbing osteoclasts, and "sensor" osteocytes. G protein-coupled receptors (GPCRs) serve as the primary "switchboard" for this complex ecosystem, translating extracellular signals into cellular responses.
While GPCRs are the targets of roughly 33% of all FDA-approved drugs, their specific roles within the skeletal system have historically been studied in isolation. This review, published in the International Journal of Biological Sciences (2025), addresses the need for a unified, cell-specific catalog of GPCR functions. By mapping nearly 100 receptors across various bone cell lineages, the authors establish a multidimensional framework for understanding skeletal homeostasis and designing the next generation of precision therapies.
Molecular Signaling Mechanisms
GPCRs function by activating specific intracellular signaling pathways categorized by their G-protein subunits: Gs, Gi, Gq, and G12/13. These pathways dictate the cellular response to ligands, ranging from transcriptional changes to mechanical sensing.
Most pro-osteogenic (bone-building) GPCRs operate through the Gs-cAMP-PKA-CREB axis. Conversely, many inflammatory and resorptive pathways are driven by Gq-PLC-β or NF-κB signaling. The Gi pathway often acts as a counter-regulator, inhibiting cAMP production, while the G12/13 pathway is frequently involved in cytoskeletal reorganization and cell migration via RhoGEF and ERK signaling.
Cell-Specific Functional Heterogeneity
A central insight of this review is that the same receptor can have opposing effects depending on the cell type or the nature of the stimulus. This "functional heterogeneity" is exemplified by the Parathyroid Hormone 1 Receptor (PTH1R).
As shown in Figure 4, PTH1R activation in MSCs promotes proliferation and osteogenic differentiation. In osteoblasts, it facilitates bone formation, while in chondrocytes, it inhibits hypertrophic differentiation to maintain cartilage health. Furthermore, the timing of stimulation matters: intermittent PTH stimulation promotes bone formation, whereas continuous stimulation can lead to bone resorption by altering the RANKL/OPG ratio in osteoblasts, which in turn regulates osteoclast activity.
The review catalogs these diverse roles across five primary categories:
- MSCs (12 GPCRs): Regulate lineage specification and stemness.
- Osteoblasts/Osteocytes (21 GPCRs): Mediate matrix mineralization and mechanotransduction.
- Macrophages/Osteoclasts (23 GPCRs): Govern resorption and immuno-skeletal crosstalk.
- Chondrocytes (31 GPCRs): Manage cartilage maintenance and endochondral ossification.
- Other Cell Types (8 GPCRs): Modulate metastasis and systemic metabolism.
Methodological Innovations in Bone Research
The field is shifting from broad "on/off" switches to precise molecular tuning, driven by several key technologies:
- Cryo-Electron Microscopy (Cryo-EM): High-resolution structural analysis allows researchers to see how receptors like PTH1R stabilize specific signaling states, facilitating the design of more effective ligands.
- Single-cell RNA Sequencing (scRNA-seq): This technology has enabled the creation of a "GPCR atlas," mapping receptor expression across the heterogeneous populations found in the bone marrow niche.
- Biased Agonism: This strategy involves designing ligands that selectively activate one intracellular pathway (e.g., G-protein signaling) while avoiding another (e.g., β-arrestin recruitment), potentially reducing the side effects of traditional drugs.
Clinical Implications and Future Directions
The authors argue that the future of bone medicine lies in allosteric modulation—targeting sites outside the main binding pocket to fine-tune receptor activity rather than blocking it entirely. This approach, combined with AI-driven drug discovery, aims to restore skeletal equilibrium in conditions like osteoporosis and rheumatoid arthritis.
However, challenges remain. Most current data is derived from isolated cell cultures, and we still lack a complete understanding of the systemic "dialogue" between different cell types in vivo. Future research must focus on disease-stage specificity, as GPCR expression profiles likely evolve as conditions like osteoarthritis progress. The development of a comprehensive "Single-cell GPCR atlas" will be a critical step toward truly personalized regenerative medicine.
Summary updated